<DOC>
	<DOCNO>NCT02121535</DOCNO>
	<brief_summary>The study perform open-label , randomised , single-dose , two-sequence , four-period replicate crossover design . A total 72 Japanese healthy male subject randomise 2 group . The subject administrate either T80/A5/H12.5 mg FDC tablet T80/A5 mg FDC tablet hydrochlorothiazide ( HCTZ ) 12.5 mg tablet period . The length admission 7 day period .</brief_summary>
	<brief_title>Bioequivalence Study Telmisartan Between T80/A5/H12.5 mg FDC Tablet T80/A5 mg Tab H12.5 mg Tab Concomitant Use</brief_title>
	<detailed_description />
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Inclusion criterion : Healthy male subject age =20 =35 year ; body weight : =50 kg =80 kg ; body mass index : =18.0 =25.0 kg/m2 Without clinically significant finding complication basis complete medical history , include physical examination , vital sign ( blood pressure ( BP ) , pulse rate ( PR ) , body temperature ) , 12lead electrocardiogram ( ECGs ) , clinical laboratory test Signed date write informed consent prior admission trial accordance Good Clinical Practice ( GCP ) local legislation . Exclusion criterion : Any find medical examination ( include BP , PR ECGs ) deviate normal clinical relevance .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>